Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics (NASDAQ:OVID) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Is OVID or OCGN more profitable?

Ovid Therapeutics has a net margin of -574.44% compared to Ocugen's net margin of -1,197.71%. Ovid Therapeutics' return on equity of -58.87% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-574.44%	-58.87%	-43.18%
Ocugen	-1,197.71%	-255.25%	-86.79%

Does the media favor OVID or OCGN?

In the previous week, Ovid Therapeutics had 1 more articles in the media than Ocugen. MarketBeat recorded 3 mentions for Ovid Therapeutics and 2 mentions for Ocugen. Ocugen's average media sentiment score of 0.91 beat Ovid Therapeutics' score of 0.50 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, OVID or OCGN?

Ovid Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, indicating that its stock price is 320% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of OVID or OCGN?

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has better earnings & valuation, OVID or OCGN?

Ovid Therapeutics has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$570K	195.86	-$26.43M	-$0.53	-2.96
Ocugen	$4.05M	116.20	-$54.05M	-$0.20	-8.05

Do analysts rate OVID or OCGN?

Ovid Therapeutics presently has a consensus target price of $3.70, suggesting a potential upside of 135.67%. Ocugen has a consensus target price of $7.00, suggesting a potential upside of 334.78%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Ocugen	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Ovid Therapeutics beats Ocugen on 12 of the 17 factors compared between the two stocks.